Sun Pharma Advanced Research Company (SPARC) has suffered setback during the fourth quarter ended March 2015 and its net loss increased sharply to Rs. 9.40 crore from Rs. 2.51 crore in the corresponding period of last year. The higher loss is due to stagnant sales and higher charges for clinical trials. Its net sales improved marginally to Rs. 42.70 crore from Rs. 42.57 crore. Its EPS worked out to negative Rs.0.40 as against negative Rs. 0.11 in the last period. Clinical trials and professional charges increased to Rs. 27.75 crore from Rs. 17.87 crore in the last period.
Despite poor financial performance, SPARC scrip moved up by Rs. 7.70 to Rs. 413.75 on BSE today. The scrip touched to its highest level at Rs. 598 on March 10, 2015.
For the full year ended March 2015, SPARC's net sales declined by 6.8 per cent to Rs. 155.74 crore from Rs. 167.03 crore in the previous year. It incurred a net loss of Rs. 39.52 crore as against a net profit of Rs. 30.32 crore. Lower sales and higher input cost put pressure on bottom line. Clinical trials and professional charges went up sharply by 110 per cent to Rs.110.61 crore from Rs. 52.74 crore in the previous year.